Delivering RNAi-Based Therapeutics & Diagnostics
Challenges & Opportunities
This cutting edge & insightful report can be used to interpret & assess the potential of RNAi-based medicines. It provides opinions & market projections to:
Assess the commercial potential of RNAi-based... |
Expanding Applications of Personalized Medicine
Use of Biomarkers in Prognostic, Predictive and Pharmacogenetic Tests in a Targeted Approach
Personalized medicine is the tailoring of medical treatment to specific groups of patients, rather than to the population as a whole. Over the past decade, several significant advances in targeted... |
Stakeholder Opinions: Hepatocellular cancer
Introduction
Despite the approval of Nexavar (sorafenib; Onyx pharmaceuticals/Bayer), patient outcomes remain poor. The large patient population and the lack of effective agents are driving R&D interest. The majority of pipeline... |
Targeted Therapies in Oncology
A World Review
The dogma for treatment of cancer has changed, with the cytotoxic drugs used in chemotherapy regimes set to lose their dominance and be used alongside targeted therapies that are being... |
Lymphoma
A Therapeutic & Competitive Insight
Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin's disease (characterized by the growth of... |
Global Pipeline Review & Analysis of Hematological Malignancies
Introduction
The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to... |
Stakeholder Opinions: Ovarian Cancer
Approaching the era of molecular targeted therapy
Introduction
Despite advances in the management of the disease, outcomes remain
poor for patients with advanced epithelial ovarian cancer. The high
level of unmet need, coupled with the large size of... |
Pipeline Insight: Colorectal Cancer
Growing trend towards personalized medicine
Introduction
CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel,... |
Immunotherapies and Vaccines for Cancer and Infectious Diseases
The field of therapeutic vaccines and immunotherapies is rapidly emerging as a promising area. Use of passive immunotherapy (i.e., antibody) products, for prevention of infection or for treatment of many... |
Competitor Analysis: PSMA & PSA Targeted Therapy
Product description
The present Competitive Intelligence Report about PSMA & PSA Targeted Therapy provides a competitor evaluation in the field of molecules targeting prostate specific membrane antigen (PSMA) or prostate specific... |
Commercial Insight Top 20 cancer therapy brands forecast
Introduction
The top 20 cancer therapies achieved sales of over $30 billion in 2009 accounting for 75% of all cancer therapy sales. The commercial success experienced by the key companies in... |
R&D Trends: Prostate Cancer
Newly approved therapies shift treatment dynamics for castrate-resistant disease
Introduction
The late-phase prostate cancer pipeline is dominated by targeted therapies, closely followed by immunotherapies. There are a growing number of therapies with novel targets such as Zibotentan (AstraZeneca) which targets... |
Oncology Adjuvants
Technologies and Global Markets
This report covers the current status of the global oncolytic adjuvant marketplace and assess its growth potential over the five-year period from 2010 to 2015.
Highlights:
The global human oncology adjuvants market... |
Oncology Market Leaders
Analyses and Outlook – 2010-2025
Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in... |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
Introduction
Non-small cell lung cancer accounts for about 80% of all lung cancers. In 2008, the incidence of NSCLC is forecast to exceed 367,000 new cases in the seven major pharmaceutical... |
Cancer Therapeutics
Market Insight and R&D Pipeline Analysis
Objectives and Scope
The intention of this study is to provide a detailed and thorough analysis of the present and future global market for cancer therapeutics. This report analyzes in detail... |
Pipeline Insight: Cancer Overview
Gastrointestinal, Skin, Sarcomas
Introduction
In 2008, the six tumor types covered in this report are forecast to account for over 961,000 new cases of cancer. Collectively, the 32 different drugs in Phase III development... |
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis
With over 50% of all non-small cell lung cancer (NSCLC) patients
diagnosed at the advanced stages of the disease, and 95% of all
small-cell lung cancer (SCLC) patients unsuitable for surgical
resection, drug... |
Cancer Therapies: Technologies and Global Markets
Study Objectives
Bcc's Goal In Conducting This Study Is To Provide An Overview Of The Current And Potential Aspects Of The Global Market For Cancer Therapies. The Report Determines The Market... |
Innovations in Protein Kinase Therapies: Company pipelines, therapeutic applications and market forecasts
During the last decade, approvals for several first-in-class kinase inhibitors have resulted in a wider recognition of kinases as an important class of drug targets. In the cancer market, there... |
Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs
Healthcare
Introduction
Only 15-20% of pancreatic cancer patients have resectable disease, therefore most receive systemic therapy. Gemzar (gemcitabine; Eli Lilly) forms the current standard of care for advanced disease. Despite this, no... |
Immunotherapy of Cancer
Cancer immunotherapeutics, in particular monoclonal antibody-based products and vaccines, are transforming the cancer treatment market and providing a whole new arsenal of weapons. The introduction of the first monoclonal antibody... |
Cancer Cell Therapy Markets
Traditionally, treatment of disease is carried out by small molecules that target specific cell types. In diseases such as cancer, the treatment is meant to kill cancer cells, leading to... |
Stakeholder Opinions: Gynecological Cancers
Niche opportunities in advanced disease
Introduction
Cases of endometrial cancer are set to rise in developed countries due to an increase in risk factors such as obesity. In contrast, while incidence of cervical cancer is set... |
Cancer Therapies
Global Market Opportunities
Cancer therapies are geared towards controlling the growth of cancerous tumors, and preventing the spread of cancer to other organs of the body. Cancer care is becoming a prime concern... |
Target Atlas in Oncology Drug Development: Targeted Therapies
With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent,... |
Liver Cancer Drugs
This report analyzes the Global market for Liver Cancer Drugs in US$ Million. Annual estimates and forecasts are provided for the period 2007 through 2015. The report profiles 40 companies... |
Pipeline Insight: Breast Cancer
Recent approvals increase pressure on pipeline candidates
Introduction
Incidence of breast cancer in the seven major markets will total 455,000 in 2008, while 115,000 women will die from the disease. Despite advances in treatment over the past decade,... |
Pipeline Insight: Therapeutic Cancer Vaccines
A turbulent path from bench to bedside
Introduction
Unmet needs across the cancer market remain high, with most therapies conferring low levels of specificity and high toxicity. Therapeutic cancer vaccines offer an attractive therapeutic addition, delivering treatment of... |
